Literature DB >> 29958976

Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement.

S P van Mens1, T Ten Doesschate2, M F Q Kluytmans-van den Bergh3, J W Mouton4, J W A Rossen5, C Verhulst6, M J M Bonten7, J A J W Kluytmans8.   

Abstract

OBJECTIVES: The increasing use of fosfomycin requires reliable susceptibility testing in clinical practice. The reference standard, agar dilution (AD), is rarely used in routine settings. The fosfomycin Etest (BioMérieux) is frequently used, although reading MICs can be hampered by the interpretation of the growth of macrocolonies in the inhibition zone. We investigated the interobserver (IO), interlaboratory (IL), and interobserver-interlaboratory (IOIL) agreement of the fosfomycin Etest and evaluated the agreement with AD.
METHODS: Etests were performed for 57 extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae of four bacterial species (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Enterobacter cloacae) in two laboratories. Photographs of fosfomycin Etests were interpreted by four observers following manufacturer's instructions.
RESULTS: Essential agreement (EA) and categorical agreement (CA) between Etest and AD were 57% and 89% (κ-value 0.68), respectively, with an underestimation of Etest interpretations compared with AD of 0.26 (95% confidence interval [CI] 0.03-0.48) 2-fold dilutions. Between Etest observations, IO-EA and -CA were reached in 82% and 94% of comparisons; IL-EA and -CA in 38% and 85% of comparisons; and IOIL-EA and -CA in 40% and 85% of comparisons, respectively. Agreement of the Etest with AD and between Etests was better for E. coli than for other species. Ignoring all macrocolonies and haze during Etest interpretation improved the agreement with AD (CA κ-value 0.80) and between Etests (CA κ-value from 0.68 to 0.81).
CONCLUSIONS: In this study on 57 ESBL-producing Enterobacteriaceae, IOIL agreement was low with an EA of 40% and a CA of 85%, affected most by IL agreement and to a lesser extent by IO agreement.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility testing; Enterobacteriaceae; Etest; Fosfomycin

Mesh:

Substances:

Year:  2018        PMID: 29958976     DOI: 10.1016/j.ijantimicag.2018.06.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci.

Authors:  James A Karlowsky; Melanie R Baxter; Alyssa R Golden; Heather J Adam; Andrew Walkty; Philippe R S Lagacé-Wiens; George G Zhanel
Journal:  J Clin Microbiol       Date:  2021-09-08       Impact factor: 5.948

2.  Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species.

Authors:  A Goer; L S Blanchard; A Van Belkum; K J Loftus; T P Armstrong; S G Gatermann; D Shortridge; B J Olson; J K Meece; T R Fritsche; M Pompilio; D Halimi; C Franceschi
Journal:  J Clin Microbiol       Date:  2022-06-23       Impact factor: 11.677

3.  Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Nancy M Laing; Melanie R Baxter; Heather J Adam; George G Zhanel
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

4.  Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.

Authors:  Iain J Abbott; Elke van Gorp; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test.

Authors:  Peter D Croughs; Michelle Konijnendijk-de Regt; Erlangga Yusuf
Journal:  Microbiol Spectr       Date:  2022-03-30

Review 6.  Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.

Authors:  Andrea Marino; Stefano Stracquadanio; Carlo Maria Bellanca; Egle Augello; Manuela Ceccarelli; Giuseppina Cantarella; Renato Bernardini; Giuseppe Nunnari; Bruno Cacopardo
Journal:  Infect Dis Rep       Date:  2022-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.